02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
19:33 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest promoting CTNNB1 citrullination or PAD2 expression could help treat colorectal cancer. Screening of approved drugs in HEK cell-based assays of CTNNB1 signaling and cell line-based citrullination...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

NT-300: Phase III started

Romark began a double-blind, placebo-controlled, international Phase III trial to compare twice-daily 600 mg NT-300 alone or in combination with twice-daily 75 mg oral Tamiflu oseltamivir for 5 days vs. Tamiflu alone or placebo in...
08:00 , Nov 8, 2012 |  BC Innovations  |  Tools & Techniques

MuSIC by design

A Harvard Medical School and Tsinghua University team has developed a technology, dubbed MuSIC, that identifies synergistic drug pairs. 1 The group showed proof of concept by finding new combinations of therapeutics for HIV, but...
07:00 , Oct 25, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Multiplex screening for interacting compounds (MuSIC) to help identify drug combinations to treat HIV/AIDS MuSIC could be used to help identify drug combinations to...
07:00 , Aug 25, 2011 |  BC Innovations  |  Targets & Mechanisms

More than one way to stop HCV

A French team led by...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Pilot trial data

An open-label pilot trial in 5 liver transplant patients showed that oral Alinia reduced HCV viral load in all patients during the first 72 hours post-transplant. However, HCV RNA levels were similar to pre-transplant levels...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II start

Next half, Intercell AG (VSE:ICLL; OTCQX:INRLY, Vienna, Austria) and Romark will begin a European Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's nitazoxanide with or without Pegasys...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Clinical News

Hepatitis C vaccine: Phase II start

Next half, Intercell and Romark Laboratories L.C. (Tampa, Fla.) will begin a European Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's nitazoxanide with or without Pegasys peginterferon...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II data

Chugai, a subsidiary of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), has exclusive rights to develop and commercialize Alinia in Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Alinia for oral suspension and Alinia tablets...